Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Composition : Methylergometrine (0.125mg)
Dosage Form : Injection
Packaging Type :
Packaging :
Price : ₹1/-
Utilair 0.125 Injection contains Methylergometrine (0.125mg), an ergot alkaloid that plays a vital role in controlling postpartum bleeding caused by uterine atony. After childbirth, if the uterus fails to contract properly, excessive bleeding can occur, leading to life-threatening conditions. This injection helps stimulate uterine contractions, which is essential for reducing blood loss and stabilizing the patient’s condition.
Administered by a healthcare professional, Utilair 0.125 Injection is primarily used in obstetrics, specifically in situations where there is a risk of postpartum hemorrhage, a common complication after delivery. Methylergometrine’s action aids in controlling excessive bleeding by promoting the contraction of the uterus, ensuring that it returns to its normal size and reducing the risk of further blood loss.
This injection is typically used in a clinical or hospital setting, ensuring close monitoring of the patient to avoid any adverse reactions. It provides quick and effective control over postpartum hemorrhage, a crucial part of post-delivery care. The dosage and timing of the injection are determined by the healthcare provider based on the patient's condition.
Possible side effects include nausea, vomiting, headache, dizziness, and high blood pressure. Rarely, more severe reactions such as vasoconstriction and seizures may occur.
Utilair 0.125 Injection is indicated for the prevention and management of postpartum hemorrhage due to uterine atony, assisting in the contraction of the uterus after childbirth.
Administer only under the supervision of a healthcare provider. Not suitable for patients with hypertension or cardiovascular disorders without prior consultation.
Composition : Bromfenac (0.09% w/v) + Moxifloxacin (0.5% w/v)
Composition : Bromfenac (0.9mg) Eye Drops
Composition : Carboxymethylcellulose (3mg/ml) + Glycerin (10mg/ml) + n-acetylcarnosine (10mg/ml)
Composition : Dexamethasone (0.1% w/v) + Tobramycin (0.3% w/v)
Composition : Fluconazole (0.3% w/v)
Composition : Gatifloxacin (0.3% w/v)
Composition : Ketorolac (0.4% w/v) + Olopatadine (0.1% w/v)
Composition : Ketorolac (0.5% w/v)
Composition : Ketorolac (5% w/v) + Moxifloxacin (0.5% w/v)
Composition : Loteprednol etabonate (0.5% w/v)